AUCTORES
Globalize your Research

Journal of Clinical Research and Reports
Ma Ping *

Open Access

Review Article

# A Review of the Current Status and Development Trends of Monkeypox POCT Detection

**Yu Fangfang [2]*, Hu Yue [2]*, Yang Xiaohui [3], Josh Z. Lee [4], Ma Ping [1,2#]**

[1]State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious diseases, Wuhan, 430072, China.

[2]Tianjin Second People's Hospital, Tianjin 300100, China.

[3]Department of Clinical Immunology, School of Medical Laboratory, Tianjin Medical University, Tianjin 300203, China.

[4]Beijing Mic Vic Biotech Co., Ltd., Beijing 101200, China.

*These authors contributed equally to this work.

***Corresponding Author:** Ma Ping, State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious diseases, Wuhan,430072, China.

**Received date:** August 04, 2025; **Accepted date:** August 15, 2025; **Published date:** August 21, 2025

**Citation:** Yu Fangfang, Hu Yue, Yang Xiaohui, Josh Z. Lee, Ma Ping, (2025), A Review of the Current Status and Development Trends of Monkeypox POCT Detection, *J Clinical Research and Reports*, 20(5); **DOI:10.31579/2690-1919/566**



## Abstract

Monkeypox, a zoonotic orthopoxvirus first identified in 1958, re-emerged in 2022 as a global health crisis, with over 84,000 cases reported across 110 countries. This unprecedented outbreak underscored the virus's capacity for human-to-human transmission and its potential to exploit gaps in diagnostic preparedness. Historically confined to Central and West Africa, monkeypox's spread to non-endemic regions revealed vulnerabilities in healthcare systems, particularly in distinguishing it from other rash-inducing illnesses (e.g., chickenpox, herpes) and in delivering equitable testing access. Current diagnostic gold standards, such as PCR, offer high sensitivity but remain centralized and resource-intensive, leaving low-income regions underserved. Emerging technologies, including microfluidic devices, CRISPR-based platforms, isothermal amplification, and AI-driven genomic surveillance, promise to revolutionize point-of-care testing and outbreak tracking. This review synthesizes the virology, epidemiology, and transmission dynamics of monkeypox, critically evaluates existing diagnostic frameworks, and explores innovations poised to address persistent challenges. By situating the 2022 and 2024 outbreaks within the broader context of persistent challenges presented by unpredictable zoonotic threats, this analysis underscores the critical need for scalable, accessible diagnostics to manage emerging risks and advance equitable pandemic preparedness worldwide.

**Keywords:** monkeypox; poct detection; rapid detection; public health; pathogenicity

## 1.Introduction

Monkeypox, a viral disease caused by the monkeypox virus (MPXV), has garnered significant global attention due to its recent outbreaks in non-endemic regions. Historically, monkeypox was primarily confined to Central and West Africa, where it was endemic among certain animal populations. However, the landscape of this disease has changed dramatically in recent years, particularly following the resurgence of cases in 2022, which prompted the World Health Organization (WHO) to declare it a Public Health Emergency of International Concern. The clinical presentation of monkeypox is similar to smallpox, characterized by fever, lymphadenopathy, and a distinctive rash that progresses through various stages. The disease is transmitted via direct contact with infected individuals or animals, as well as through contaminated materials, which has raised concerns about its potential for human-to-human transmission and the implications for public health on a global scale[1–4].

The expansion of monkeypox beyond its traditional endemic regions highlights the urgent need for effective diagnostic tools to facilitate timely identification and management of cases. Current diagnostic methods, such as real-time quantitative polymerase chain reaction (qPCR), are considered the gold standard for detecting MPXV. However, these methods often require specialized laboratory facilities, equipment and trained personnel, which may not be readily available in resource-limited settings. As a result, there is a pressing demand for point-of-care testing (POCT) solutions that can provide rapid, sensitive, and specific detection of monkeypox. POCT technologies have gained traction due to their portability and ease of use, making them ideal for deployment in various healthcare settings, particularly in response to outbreaks[5, 6].

Recent advancements in POCT for monkeypox and infectious disease detection have shown promising results, demonstrating the potential to revolutionize the management of this disease. Novel diagnostic approaches, such as CRISPR-based assays, lateral flow immunoassays, and microfluidic devices, have been developed to enhance the sensitivity and specificity of monkeypox detection. For instance, a CRISPR-Cas12a-based detection system targeting the MPXV A27L gene has achieved a remarkable detection limit, enabling rapid diagnosis directly from clinical samples[7]. Additionally, the development of affordable microfluidic devices holds great promise for improving the accessibility of monkeypox testing, particularly in regions with limited healthcare infrastructure[8, 9].

The emergence of monkeypox in non-endemic countries underscores the importance of developing robust surveillance systems and rapid response strategies. Effective monitoring and control of monkeypox outbreaks necessitate not only the availability of reliable diagnostic tools but also the implementation of public health measures aimed at reducing transmission. This includes vaccination campaigns, contact tracing, and public awareness initiatives to educate communities about the risks associated with monkeypox and the importance of seeking medical attention when symptoms arise[10]. Furthermore, ongoing research into the epidemiology and transmission dynamics of monkeypox will be crucial for informing future prevention and control strategies.

In conclusion, the recent resurgence of monkeypox has highlighted critical gaps in pandemic preparedness, including the need for equitable access to effective diagnostics. POCT technologies represent a vital component of the response to monkeypox, offering the potential for rapid and accurate detection in a wide range of healthcare settings. The re-emergence of MPXV underscores the interconnectedness of human, animal, and environmental health, as researchers continue to explore and refine these diagnostic approaches, it is essential to integrate them into broader public health strategies to mitigate future zoonotic spillover and address systemic vulnerabilities in global surveillance[11]. Here, we summarize and explore the most recent POCT technologies that can offer de-centralized, accessible, and low-cost diagnostics for use in the management of future outbreaks to improve global response to monkeypox.

## 2.1 Pathogenic Characteristics of Monkeypox Virus

### 2.1.1 Virus Classification and Structure

Monkeypox virus (MPXV) is a member of the Orthopoxvirus genus within the Poxviridae family. This classification places it in close relation to other notable viruses such as variola virus (the causative agent of smallpox), vaccinia virus (used in the smallpox vaccine), and cowpox virus. MPXV is characterized as a linear double-stranded DNA virus with a relatively large genome, which allows for a variety of genetic mutations and adaptations. The virus exhibits a brick-shaped morphology, typical of poxviruses, and is enveloped by a lipid membrane that contains various proteins essential for its infectivity and immune evasion[2].

The structural components of MPXV include the viral core, which houses the genetic material, surrounded by a proteinaceous layer known as the lateral body, and a lipid envelope. This structure is crucial for the virus's ability to enter host cells and evade the host immune response. The envelope contains glycoproteins that facilitate attachment to host cell receptors, initiating the infection process. Understanding the structural biology of MPXV is vital for developing targeted antiviral therapies and vaccines, as well as for enhancing diagnostic methods[12].

### 2.1.2 Transmission Routes and Epidemiology

Historically, monkeypox has been endemic to regions of Central and West Africa, primarily transmitted to humans through zoonotic spillover from infected animals, particularly rodents and primates. The recent global outbreak, which began in 2022, has highlighted a shift in transmission dynamics, with increased human-to-human transmission observed, particularly among men who have sex with men (MSM) [3, 13]. This change in epidemiology underscores the virus's adaptability and raises concerns about its potential to establish endemicity in non-traditional regions.

Transmission occurs through direct contact with infectious lesions, bodily fluids, or respiratory droplets from an infected individual. The virus can also be transmitted via contaminated objects, such as bedding or clothing, further complicating control measures. The incubation period for MPXV ranges from 5 to 21 days, with symptoms typically including fever, lymphadenopathy, and a characteristic rash that progresses through various stages[14]. The 2022 outbreak has seen confirmed cases reported in 112 countries, emphasizing the need for robust surveillance and public health interventions to mitigate further spread[3, 15].

### 2.1.3 Clinical Manifestations and Diagnostic Challenges

The clinical presentation of monkeypox can vary significantly, complicating diagnosis. Initial symptoms often resemble those of other viral infections, including fever, malaise, and lymphadenopathy. The distinctive rash typically appears 1 to 3 days after the onset of fever, progressing from macules to papules, vesicles, and pustules before crusting over[16]. Notably, the rash can present atypically, particularly in immunocompromised individuals, leading to misdiagnosis or delayed treatment[14].

Diagnostic challenges arise due to the overlap in clinical features with other conditions, such as varicella (chickenpox) and herpes simplex virus infections. Laboratory confirmation is essential, with real-time polymerase chain reaction (RT-PCR) being the gold standard for MPXV detection. However, the requirement for specialized equipment and trained personnel can limit access to timely diagnosis, particularly in resource-limited settings[17]. Emerging diagnostic technologies, including CRISPR-based assays, microfluidics, and point-of-care testing (POCT) methods, show promise in enhancing the speed and accuracy of MPXV detection, potentially addressing some of these challenges[7, 18].

In summary, the pathogenic characteristics of monkeypox virus encompass its classification, structural biology, transmission dynamics, and clinical manifestations. The ongoing global outbreak necessitates a comprehensive understanding of these aspects to inform public health strategies, improve diagnostic capabilities, and develop effective therapeutic interventions.

## 2.2 Overview of POCT Testing Technology

### 2.2.1 Definition and Advantages of POCT Technology

Point-of-care testing (POCT) refers to diagnostic tests performed at or near the site of patient care, allowing for immediate results and timely clinical decision-making. This approach is highly beneficial in various healthcare settings, including emergency departments, outpatient clinics, and even at home. The primary advantages of POCT technology include rapid turnaround times, ease of utilization, reduced need for laboratory infrastructure, and improved patient management through immediate feedback. Studies have shown that POCT can significantly enhance the efficiency of healthcare delivery by providing timely diagnostic information, which is crucial for managing both acute and chronic diseases alike. Furthermore, POCT devices are typically designed to be user-friendly, allowing healthcare professionals and patients to perform tests with minimal training. This accessibility is especially important in resource-limited settings where traditional laboratory services may be unavailable or delayed. POCT can lead to improved patient outcomes by facilitating quicker treatment decisions and reducing the time to diagnosis, ultimately contributing to better disease management and control[19, 20]

Moreover, the integration of advanced technologies, such as mobile applications and telemedicine, with POCT has further enhanced its capabilities. For instance, smartphone-based POCT devices can transmit test results directly to healthcare providers, enabling remote monitoring and consultations. This feature is particularly advantageous in managing infectious diseases, as it allows for real-time tracking of disease outbreaks and patient health status[21–23]. The potential for POCT to bridge the gap between patients and healthcare providers is immense, especially in the context of global health challenges such as the COVID-19 pandemic, where rapid testing and isolation measures are critical[12].

#### 2.2.2 Commonly Used POCT Devices and Methods

A variety of POCT devices and methods are currently employed across different medical fields, each designed to address specific diagnostic needs. Commonly used POCT devices include lateral flow assays (LFAs), glucose meters, and molecular diagnostic platforms. LFAs are particularly popular due to their simplicity and rapid results, making them ideal for testing infectious diseases like HIV, malaria, and more recently, monkeypox[17, 20]. These tests typically involve a sample being applied to a test strip that contains specific antibodies or antigens, allowing for visual interpretation of results within minutes.

Glucose meters are among the most widely utilized POCT devices, especially for diabetes management. Recent advancements have led to the development of personal glucose meters that can detect non-glucose targets, demonstrating the versatility of these devices[7]. Additionally, molecular diagnostic methods, such as polymerase chain reaction (PCR) and CRISPR-based assays coupled with portable devices[18], are increasingly being adapted for POCT applications. These methods offer high sensitivity and specificity, making them suitable for detecting various pathogens, including viral and bacterial infections[12, 24].

Emerging technologies, such as microfluidic devices and wearable sensors, are also gaining traction in the POCT landscape. Microfluidic devices, often referred to as "lab-on-a-chip" systems, enable multiple tests to be conducted simultaneously on a single chip, significantly reducing the time and resources required for testing[8, 9, 25]. Wearable sensors, on the other hand, allow for continuous monitoring of health parameters, providing real-time data that can be crucial for managing chronic conditions[26]. The integration of these advanced technologies into POCT not only enhances diagnostic capabilities but also contributes to personalized medicine by allowing for tailored treatment approaches based on individual patient data[27].

In summary, POCT technology encompasses a diverse range of devices and methods that provide rapid, accurate, and accessible diagnostic solutions. The ongoing advancements in this field hold great promise for improving healthcare delivery and patient outcomes across various medical domains.

### 2.3 Current POCT Detection Methods for Monkeypox

The emergence of monkeypox as a significant global health concern necessitates the development of effective point-of-care testing (POCT) methods. These methods are essential for rapid diagnosis, particularly in resource-limited settings where traditional laboratory facilities may not be available[28]. Current POCT methods for monkeypox focus on various aspects, including sample collection and processing techniques, detection principles and workflows, and a comparative analysis of existing market products.

#### 2.3.1 Sample Collection and Processing Techniques

Sample collection and processing are critical steps in the accurate detection of the monkeypox virus (MPXV). The choice of sample type can significantly impact the sensitivity and specificity of the diagnostic tests. Recent studies have highlighted various sample types, including skin lesions, saliva, and oropharyngeal swabs, as viable options for MPXV detection. For instance, herpes fluid and saliva have been identified as particularly suitable sources for testing, demonstrating a high correlation with qPCR results, which is considered the gold standard for MPXV detection[12].

The integration of innovative sample processing techniques also enhances the efficiency of POCT. For example, the use of magnetic bead-based nucleic acid extraction methods has been shown to improve the sensitivity and specificity of loop-mediated isothermal amplification (LAMP) assays, achieving sample-to-answer detection within one hour[29, 30]. Additionally, advancements in portable devices enable rapid and accurate sample processing, essential for effective outbreak management in field settings[17]. The development of integrated devices that combine sample collection, processing, and detection capabilities streamlines the diagnostic workflow, making it more accessible for healthcare providers in various settings[6, 17, 24].

#### 2.3.2 Detection Principles and Workflows

The detection of monkeypox virus employs various principles and methodologies, each with distinct advantages and limitations. The most common techniques include polymerase chain reaction (PCR), CRISPR-based assays, and lateral flow assays (LFAs). PCR remains the gold standard due to its high sensitivity and specificity; however, it requires specialized equipment and trained personnel, which may not be available in all healthcare settings[12].

Emerging technologies, such as CRISPR-Cas12a-based detection systems, have shown promise in providing rapid and accurate results. These systems can achieve detection limits as low as 10 aM and deliver results in under 40 minutes, making them suitable for POCT applications[12]. Moreover, the integration of CRISPR technology with lateral flow assays allows for visual result interpretation, enhancing usability in low-resource environments[24].

LAMP assays represent another innovative approach, providing rapid results without the need for complex instrumentation. The development of colorimetric LAMP assays has demonstrated high sensitivity and specificity, with the ability to visually detect MPXV within one hour[29]. These assays can be particularly beneficial in emergency settings where timely diagnosis is crucial for outbreak control.

These innovations collectively address critical barriers in POCT, making advanced diagnostics more accessible, reliable, and efficient for global health applications.

#### 2.3.3 Existing Products and Comparison

The market for monkeypox detection products is rapidly evolving, with several innovative solutions emerging to address the urgent need for effective diagnostics. A comparative analysis of existing products reveals a range of performance characteristics, including sensitivity, specificity, and ease of use. For instance, lateral flow assays based on upconversion nanoparticles have been developed, offering dual-mode detection capabilities with rapid readout times of less than 8 minutes[20]. These assays exhibit lower limits of detection compared to traditional methods, making them highly competitive in the POCT landscape.

Another notable product is the DMSO-enhanced one-pot HDA-CRISPR/Cas12a biosensor, which achieves a limit of detection of 10 fM and demonstrates high specificity in distinguishing MPXV from closely related orthopoxviruses[24]. The ability to provide rapid results while maintaining high sensitivity positions this product as a valuable tool for healthcare providers.

In addition to these advancements, the development of multiplexed biosensing platforms is gaining traction. These platforms can simultaneously detect multiple pathogens, including MPXV, which is particularly advantageous in the context of co-infections and emerging infectious diseases[31]. The integration of various detection technologies into a single platform enhances diagnostic capabilities and facilitates comprehensive patient management.

In conclusion, the current landscape of POCT methods for monkeypox detection is characterized by rapid advancements in sample collection techniques, innovative detection principles, and a diverse array of market products. As the global health community continues to address the challenges posed by monkeypox, these developments are crucial for enhancing diagnostic capabilities and improving outbreak response efforts. Continued research and investment in POCT technologies will play a vital role in controlling the spread of monkeypox and other emerging infectious diseases.

## 2.4 Application of POCT Technology in Monkeypox Outbreak Management

### 2.4.1 Early screening and diagnosis

Point-of-care testing (POCT) technology has emerged as a critical tool in the early screening and diagnosis of monkeypox virus (MPXV) infections, particularly in the context of recent outbreaks. The need for rapid and accurate diagnostic methods is underscored by the zoonotic nature of monkeypox and its potential for human-to-human transmission, especially in non-endemic regions. Traditional diagnostic methods, such as quantitative polymerase chain reaction (qPCR), while highly sensitive, require specialized laboratory facilities and trained personnel, which can delay timely diagnosis and treatment. In contrast, POCT offers a more accessible and efficient alternative. For instance, recent advancements have led to the development of a CRISPR-Cas12a-based detection system targeting the MPXV A27L gene, achieving a detection limit as low as 10 aM and providing results in under 40 minutes[7]. This rapid turnaround is crucial for initiating appropriate public health responses, especially during outbreaks.

Moreover, innovative approaches such as the use of upconversion nanoparticles-based lateral flow assays (UCNPs-LFA) have demonstrated the capability for both qualitative and quantitative detection of MPXV with a much lower limit of detection compared to existing POCT methods. This dual-mode detection system, which can be integrated with smartphones for real-time results, exemplifies the potential of POCT to enhance early diagnosis in resource-limited settings[20]. The integration of these technologies not only facilitates early identification of infected individuals but also aids in distinguishing between different clades of MPXV, which is essential given their varying transmissibility and clinical manifestations.

The ability to conduct testing at the point of care significantly reduces the time to diagnosis, thereby enabling quicker isolation of cases and implementation of control measures. Studies have shown that the use of POCT can lead to improved management outcomes in infectious diseases, as it empowers healthcare providers to make informed decisions based on immediate results[24]. Furthermore, the development of user-friendly devices that do not require extensive training can democratize access to testing, particularly in underserved regions where healthcare infrastructure may be lacking.

In conclusion, the application of POCT technology in the early screening and diagnosis of monkeypox is pivotal in managing outbreaks effectively. By facilitating rapid diagnosis, these technologies enable timely public health interventions, thereby mitigating the spread of the virus and enhancing overall epidemic response strategies.

### 2.4.2 Epidemic surveillance and containment

The role of point-of-care testing (POCT) technology extends beyond early diagnosis to encompass epidemic monitoring and control of monkeypox virus (MPXV) outbreaks. Effective surveillance systems are essential for tracking the spread of infectious diseases, and POCT provides a valuable tool for real-time monitoring of MPXV transmission dynamics. The integration of POCT into existing public health frameworks can enhance the ability to respond swiftly to emerging outbreaks, particularly in non-endemic regions where healthcare systems may be less prepared.

One of the key advantages of POCT is its capacity to facilitate widespread testing in community settings, allowing for the rapid identification of cases. This is particularly important in the context of monkeypox, where early detection can significantly impact transmission rates. For example, a study demonstrated that utilizing a rapid lateral flow assay for MPXV detection enabled healthcare providers to identify cases quickly, leading to timely isolation and treatment of infected individuals[17]. This rapid response is crucial in preventing further spread, especially in densely populated areas or regions experiencing outbreaks.

Moreover, POCT technologies can be utilized for continuous monitoring of high-risk populations, enabling public health officials to identify potential hotspots for transmission. By implementing regular screening protocols in these populations, health authorities can gather valuable epidemiological data that informs public health strategies. For instance, the use of mobile health applications linked to POCT devices can facilitate real-time data collection and analysis, allowing for the monitoring of trends in MPXV cases and the effectiveness of control measures[32].

The ability to conduct on-site testing also reduces the burden on centralized laboratories, which may become overwhelmed during outbreaks. This decentralization of testing not only improves the efficiency of the public health response but also enhances the accessibility of diagnostic services for communities[28]. Furthermore, the incorporation of POCT into surveillance systems can lead to improved compliance with testing protocols, as patients are more likely to participate in testing that is convenient and readily available.

The application of POCT technology in epidemic monitoring and control of monkeypox is instrumental in enhancing public health responses. By enabling rapid case identification and continuous surveillance, POCT supports the implementation of effective control measures, ultimately contributing to the containment of outbreaks and the protection of public health.

### 2.4.3 Clinical management and patient follow-up

Point-of-care testing (POCT) technology plays a significant role in the clinical management and follow-up of patients diagnosed with monkeypox virus (MPXV) infections. The integration of POCT into clinical workflows not only enhances the efficiency of patient management but also improves patient outcomes through timely interventions and monitoring. As monkeypox cases continue to rise globally, effective clinical management strategies are essential to mitigate the impact of the disease.

One of the primary benefits of POCT in clinical management is its ability to provide immediate diagnostic results, which facilitates prompt decision-making regarding treatment and patient care. For instance, the rapid detection of MPXV using POCT technologies allows healthcare providers to initiate appropriate antiviral therapy and supportive care without delay[33]. This is particularly crucial in managing severe cases where timely intervention can significantly alter the clinical course and reduce the risk of complications.

Furthermore, POCT can enhance patient follow-up by enabling continuous monitoring of viral load and treatment response. For example, the use of CRISPR-based assays for MPXV detection allows clinicians to assess the effectiveness of antiviral treatments in real time, guiding adjustments to therapy as needed[24]. This dynamic approach to patient management ensures that individuals receive personalized care tailored to their specific clinical needs.

In addition to direct patient management, POCT facilitates better communication and engagement with patients[34]. By providing accessible testing options, patients are more likely to participate in follow-up care and adhere to treatment protocols. This is particularly important in the context of monkeypox, where ongoing monitoring is essential for detecting potential complications or relapses. Studies have shown that patients who are actively involved in their care through regular follow-up and monitoring exhibit improved adherence to treatment regimens and better overall health outcomes[3].

Moreover, the integration of POCT into clinical management can streamline healthcare workflows, reducing the burden on healthcare providers and allowing them to focus on delivering high-quality care. By minimizing the need for laboratory-based testing and enabling on-site diagnostics, POCT can enhance the efficiency of clinical operations, particularly in resource-limited settings where healthcare infrastructure may be challenged[35].

In conclusion, the application of POCT technology in the clinical management and follow-up of monkeypox patients is crucial for improving patient outcomes and enhancing the overall quality of care. By facilitating rapid diagnosis, continuous monitoring, and patient engagement, POCT supports effective management strategies that are essential for addressing the challenges posed by monkeypox outbreaks.

## 2.5 Future Development Directions and Challenges

### 2.5.1 Improvement and Innovation of Detection Methods

The ongoing global health challenges posed by diseases like monkeypox underscore the urgent need for innovative and improved detection methods. Traditional diagnostic techniques, such as quantitative polymerase chain reaction (qPCR), while effective, often require specialized personnel and expensive equipment, making them less accessible, especially in resource-limited settings[12]. Recent advancements in point-of-care testing (POCT) have shown promise in addressing these limitations by providing rapid, on-site diagnostic capabilities. For instance, the development of a CRISPR-Cas12a-based detection system targeting specific genes of the monkeypox virus has demonstrated high sensitivity and specificity, achieving detection limits as low as 10 attomolar[7]. Furthermore, innovations such as microfluidic chip assays[8], coupled with innovations in interferometry reflectance imaging[9] and colorimetric loop-mediated isothermal amplification (LAMP) systems have been integrated into POCT frameworks, allowing for quick and visual results that can be interpreted without specialized training, while dramatically improving in sensitivity[29].

The introduction microfluidic technologies have enhanced molecular and antigen-based POCT by streamlining workflows and enhancing performance. By integrating sample preparation, reagent handling, and detection into miniaturized, automated systems, microfluidics significantly reduces manual steps, enabling even non-specialized users to conduct complex assays with minimal training[8, 9, 21, 36, 37]. This simplification, coupled with reduced reagent consumption and scalable manufacturing, drives down costs while maintaining high precision. Furthermore, microfluidic platforms enhance sensitivity through precise control of nanoliter-scale reactions and improve specificity via advanced surface functionalization or microchannel designs that minimize cross-reactivity. In the case of antigen-based detection methods, it was able to achieve picogram level sensitivity[8, 21].

Moreover, the incorporation of digital technologies into diagnostic processes has opened new avenues for enhancing detection methods. For example, the use of artificial intelligence (AI) and machine learning algorithms in image recognition tasks for diagnosing monkeypox skin lesions has shown significant potential[38]. These technologies can improve diagnostic accuracy and efficiency, allowing for faster identification of cases and better management of outbreaks. The challenge remains to ensure that these innovative methods are not only effective but also scalable and affordable for widespread use, particularly in low-resource settings where the burden of such diseases is often the highest.

### 2.5.2 Automation of Data Management and Result Interpretation

As diagnostic technologies evolve, so too does the need for efficient data management and result interpretation systems. The integration of automated data management systems can significantly enhance the speed and accuracy of disease detection and monitoring. Current practices often rely on manual data entry and analysis, which can lead to errors and delays in reporting critical health information. Automated systems can streamline these processes by utilizing electronic health records (EHRs) and real-time data analytics to capture and analyze diagnostic results promptly[39].

The development of user-friendly interfaces that allow healthcare providers to easily interpret results is also crucial. For instance, the incorporation of visual aids and decision-support systems can help clinicians make informed decisions based on diagnostic data, ultimately improving patient outcomes[40]. Additionally, the use of machine learning algorithms to analyze large datasets can identify trends and patterns in disease spread, facilitating proactive public health interventions[41].

However, the implementation of such automated systems is not without challenges. Issues related to data privacy, security, and interoperability between different health information systems must be addressed to ensure that these technologies can be effectively integrated into existing healthcare infrastructures. Furthermore, training healthcare professionals to utilize these automated systems effectively is essential to maximize their benefits and ensure accurate interpretation of results.

### 2.5.3 Public Acceptance and Education

Public acceptance of new diagnostic methods and vaccines is a critical factor in the success of public health initiatives. The recent monkeypox outbreaks have highlighted the importance of effective communication and education strategies to enhance public understanding of the disease and its prevention. Surveys have shown that knowledge levels regarding monkeypox among the general population are often inadequate, which can lead to increased anxiety and vaccine hesitancy[42].

Educational campaigns that provide clear, accessible information about monkeypox, its transmission, and the benefits of vaccination are essential. For example, targeted outreach to high-risk populations, such as men who have sex with men (MSM), can help increase awareness and acceptance of vaccination[43]. Furthermore, leveraging social media and community engagement strategies can effectively disseminate information and address misconceptions about the disease[44].

In addition to education, addressing the psychological and social factors that influence vaccine acceptance is crucial. Factors such as perceived susceptibility to infection, previous experiences with healthcare systems, and socio-economic status can significantly impact individuals' willingness to accept vaccines[40]. Tailoring educational materials to address these factors and fostering trust in healthcare providers can enhance public confidence in vaccination efforts.

Ultimately, a multifaceted approach that combines education, community engagement, and targeted communication strategies is essential to improve public acceptance of new diagnostic methods and vaccines. By empowering individuals with knowledge and addressing their concerns, public health authorities can facilitate a more effective response to emerging infectious diseases like monkeypox.

## Conclusion

The evolution of POCT has been marked by significant technological advancements, which have improved the speed, accuracy, and accessibility of diagnostic testing. These improvements are particularly crucial in the context of monkeypox, where timely identification of cases can drastically influence outbreak containment strategies. The ability to conduct rapid tests at the point of care enables healthcare providers to make informed decisions without delay, ultimately reducing transmission rates and improving patient outcomes. Moreover, POCT can play a pivotal role in epidemiological research by facilitating the collection of data in real-time, which is essential for tracking the spread of the disease and identifying potential hotspots.

However, the integration of POCT into monkeypox management is not without its challenges. For instance, while the sensitivity and specificity of POCT methods have improved, variability in test performance across different settings can undermine their reliability. Therefore, rigorous validation and standardization of POCT devices are imperative to ensure consistent results, especially in diverse geographical and clinical contexts.

Additionally, the successful implementation of POCT relies heavily on the education and training of healthcare personnel. It is crucial that practitioners are well-versed in the operational aspects of these testing modalities, including sample collection, interpretation of results, and subsequent clinical decision-making. Furthermore, public awareness campaigns are necessary to inform communities about the availability and importance of POCT in the context of monkeypox. Balancing the educational needs with the rapid deployment of these technologies requires a concerted and multidisciplinary effort from public health authorities, healthcare institutions, professionals, and educational organizations. This collaborative framework can also foster the development of innovative solutions that address both the technical and logistical challenges associated with POCT implementation.

In conclusion, while the promise of POCT in enhancing monkeypox detection and management is evident, realizing its full potential will require a nuanced understanding of the various research perspectives and findings. The path forward necessitates a delicate balance between leveraging technological advancements and addressing the inherent challenges of implementation. By fostering a collaborative environment that encourages ongoing research, education, and dialogue among stakeholders, we can pave the way for a more effective and responsive approach to managing monkeypox and similar infectious diseases in the future. Ultimately, the goal is to harness the power of POCT to not only combat current outbreaks but also to prepare for future public health challenges, thereby safeguarding communities and enhancing global health security.

## Reference


1. Jeyaraman M, Selvaraj P, Halesh MB, et al. (2022). Monkeypox: An Emerging Global Public Health Emergency. *Life Basel Switz*. October 12; 1210:1590.
2. Naga NG, Nawar EA, Mobarak AA, Faramawy AG, Al-Kordy HMH. (2025). Monkeypox: a re-emergent virus with global health implications - a comprehensive review. *Trop Dis Travel Med Vaccines*. January 15; 111:2.
3. Al-Gburi S, Namuq Z. (2022). A Review of the Recent Monkeypox Outbreak in 2022. Cureus. August;148: e27880. PMID: 36134109.
4. Ladnyj ID, Ziegler P, Kima E. (1972). A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. *Bull World Health Organ*.;465:593–597. PMID: 4340218.
5. Wang C, Liu M, Wang Z, Li S, Deng Y, He N. (2021). Point-of-care diagnostics for infectious diseases: From methods to devices. *Nano* Today. April; 37:101092. PMID: 33584847.
6. Augustine S, Venkadesh A, Kaushal S, Lee E, Ajaj M, Lee N-E. (2025). Point-of-Care Testing: The Convergence of Innovation and Accessibility in Diagnostics. *Anal Chem*. May 13; 9718:9569–9599.
7. Ding S, Dong J, Shi J, et al. (2025). Integrating commercial personal glucose meter with peroxidase-mimic DNAzyme to develop a versatile point-of-care biosensing platform. *Biosens Bioelectron*. April 1; 273:117171. PMID: 39837235.
8. Yang X, Li Y, Lee JZ, et al. (2024). A Highly Sensitive Dual-Drive Microfluidic Device for Multiplexed Detection of Respiratory Virus Antigens. *Micromachines*. May 23; 156:685. PMID: 38930655.
9. Aslan M, Seymour E, Brickner H, et al. (2024). A Label-free Optical Biosensor-Based Point-of-Care Test for the Rapid Detection of Monkeypox Virus. MedRxiv *Prepr Serv Health Sci*. July 5:2024.07.03.24309903. PMID: 39006424.
10. Javelle E, Ficko C, Savini H, et al. (2023). Monkeypox clinical disease: Literature review and a tool proposal for the monitoring of cases and contacts. *Travel Med Infect Dis*.; 52:102559. PMID: 36809829.
11. Li X, Li Y, Yu W, et al. (2023). Frontiers of monkeypox research: An analysis from the top 100 most influential articles in the field. *Heliyon*. October;910: e20566. PMID: 37822624.
12. Liu S, Yang Y, Li X, et al. (2025). Development of a single-tube RPA/CRISPR-cas12a detection platform for monkeypox virus. *Biosens Bioelectron*. June 15; 278:117221. PMID: 40054154.
13. Alshahrani NZ, Mitra S, Alkuwaiti AA, et al. (2022). Medical Students' Perception Regarding the Re-emerging Monkeypox Virus: An Institution-Based Cross-Sectional Study from Saudi Arabia. *Cureus*. August;148: e28060. PMID: 36127980.
14. Milligan AL, Koay S-Y, Dunning J. (2022). Monkeypox as an emerging infectious disease: the ophthalmic implications. *Br J Ophthalmol*. December; 10612:1629–1634. PMID: 36216412.
15. 2022-24 Mpox Outbreak: Global Trends. Geneva: World Health Organization, 2025. n.d.
16. Shafaati M, Zandi M. (2022). State-of-the-art on monkeypox virus: an emerging zoonotic disease. *Infection*. December; 506:1425–1430. PMID: 36192607.

17. Liu W, Zhang E, Li W, et al. (2024). Advances and challenges of mpox detection technology. Biosaf Health. October; 65:260–269. PMID: 40078738.
18. Wang Y, Chen H, Lin K, et al. (2024). Ultrasensitive single-step CRISPR detection of monkeypox virus in minutes with a vest-pocket diagnostic device. *Nat Commun*. April 16; 151:3279. PMID: 38627378.
19. Teebagy S, Wang Z, Dunlap D, et al. (2022). Understanding Healthcare Professionals' Perspectives on Point-of-Care Testing. *Diagn Basel Switz*. February 19; 122:533. PMID: 35204622.
20. Jin B, Ma C, Zhang C, et al. (2024). Point-of-care detection of Monkeypox virus clades using high-performance upconversion nanoparticle-based lateral flow assay. *Mikrochim Acta*. March 5; 1914:177. PMID: 38441684.
21. Liu X, He M, Hu R, Huang S, Chen Z. (2024). Point-of-Care Testing for Cardiovascular Disease: A Narrative Review. *Curr Med Chem*. October 1. PMID: 39354764.
22. Huang T, Zou Q, Chu Y, Jin J, Chen C. Zhongguo Yi Liao Qi Xie Za Zhi. (2023) [Research and Application of Smartphone-based Detection System to Immunoassay] February 8; 472:178–184. PMID: 37096472.
23. Lau C-H, Huang S, Zhu H. (2024). Amplification-free nucleic acids detection with next-generation CRISPR/dx systems. *Crit Rev Biotechnol*. September 22:1–28. PMID: 39307577.
24. Yu L, Tang Y, Sun Y, et al. (2025). DMSO enhanced one-pot HDA-CRISPR/Cas12a biosensor for ultrasensitive detection of Monkeypox virus. *Talanta*. May 15; 287:127660. PMID: 39892116.
25. Borriello M, Tarabella G, D'Angelo P, et al. (2023). Lab on a Chip Device for Diagnostic Evaluation and Management in Chronic Renal Disease: A Change Promoting Approach in the Patients' Follow Up. *Biosensors*. March 12; 133:373. PMID: 36979584.
26. Bodington R, Kassianides X, Bhandari S. (2021). Point-of-care testing technologies for the home in chronic kidney disease: a narrative review. *Clin Kidney J*. November; 1411:2316–2331. PMID: 34751234.
27. Wang X, Deng X, Zhang Y, et al. (2024). A rapid and sensitive one-pot platform integrating fluorogenic RNA aptamers and CRISPR-Cas13a for visual detection of monkeypox virus. *Biosens Bioelectron*. August 1; 257:116268. PMID: 38636316.
28. Silva SJR da, Kohl A, Pena L, Pardee K. (2023). Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions. *iScience*. June 16; 266:106759. PMID: 37206155.
29. Peng Y, Hu R, Xue S, et al. (2024). Rapid and highly sensitive colorimetric LAMP assay and integrated device for visual detection of monkeypox virus. *Anal Chim Acta*. July 4; 1311:342720. PMID: 38816155.
30. Cavuto ML, Malpartida-Cardenas K, Pennisi I, et al. (2025). Portable molecular diagnostic platform for rapid point-of-care detection of mpox and other diseases. *Nat Commun*. March 24; 161:2875. PMID: 40128193.
31. Zheng Y, Song X, Fredj Z, Bian S, Sawan M. (2023). Challenges and perspectives of multi-virus biosensing techniques: A review. *Anal Chim Acta*. March 1; 1244:340860. PMID: 36737150.
32. Li H, Zhang K-L, Kou Y, et al. (2025). Resonance SERS probe based on the bifunctional molecule IR808 combined with SA test strips for highly sensitive detection of monkeypox virus. Spectrochim Acta A Mol Biomol Spectrosc. April 15; 331:125761. PMID: 39862575.
33. Wan J, Zhang X, Qu J, et al. (2023). Investigation into the epidemiology, genetic characteristics, and clinical manifestations of the first monkeypox outbreak in Shenzhen, China. *Biosaf Health*. October; 55:259–265. PMID: 40078907.
34. Nichols JH. (2021). Utilizing Point-of-Care Testing to Optimize Patient Care. EJIFCC. June; 322:140–144. PMID: 34421482.
35. Kumar A, Borkar SK, Choudhari SG, Mendhe HG, Bankar NJ. (2023). Recent Outbreak of Monkeypox: Implications for Public Health Recommendations and Crisis Management in India. *Cureus*. September;159: e45671. PMID: 37868437.
36. Yin B, Wan X, Sohan ASMMF, Lin X. (2022). Microfluidics-Based POCT for SARS-CoV-2 *Diagnostics. Micromachines*. August 1; 138:1238. PMID: 36014162.
37. Wang N, Zhang J, Xiao B, Chen A. (2024). Microfluidic-assisted integrated nucleic acid test strips for POCT. *Talanta*. January 15; 267:125150. PMID: 37672986.
38. Eliwa EHI, El Koshiry AM, Abd El-Hafeez T, Farghaly HM. (2023). Utilizing convolutional neural networks to classify monkeypox skin lesions. *Sci Rep*. September 3; 131:14495. PMID: 37661211.
39. Chelsky ZL, Dittmann D, Blanke T, Chang M, Vormittag-Nocito E, Jennings LJ. (2022). Validation Study of a Direct Real-Time PCR Protocol for Detection of Monkeypox Virus. *J Mol Diagn JMD*. November; 2411:1155–1159. PMID: 36113759.
40. Fetensa G, Tolossa T, Besho M, et al. (2025). Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study. *Vaccine*. March 7; 49:126822. PMID: 39892112.
41. Lawrence A. (2024). Socio-Demographic Factors Influencing Monkeypox Vaccination Intentions Among Healthcare Workers and the General Population of Makurdi, Nigeria: A Cross-Sectional Study. *Cureus*. October;1610: e71828. PMID: 39429994.
42. Alqthami OA, Alaseeri RH, Alzahrani AA, et al. (2023). Assessing the Anxiety and Knowledge about Monkeypox Virus: A Cross-Sectional Cohort Study. *Cureus*. October;1510: e47806. PMID: 37899897.
43. Zheng M, Qin C, Qian X, et al. (2022). Knowledge and vaccination acceptance toward the human monkeypox among men who have sex with men in China. *Front Public Health*.;10:997637. PMID: 36388271.
44. Lounis M, Hamimes A, Dahmani A. (2024). Assessment of Monkeypox (MPOX) Knowledge and Vaccination Intention among Health and Life Sciences Students in Algeria: A Cross-Sectional Study. Infect Dis Rep. February 22; 162:170–180. PMID: 38525760.

**DOI:**10.31579/2690-1919/566